Baxter International Inc

Baxter International

BAX · NYSE

Healthcare

Catalog as of September 15, 2026. Not a live market feed.

Fiscal Year: 2025
Revenue: $11.2B
Assets: $20.1B
SEC filing: DEF 14A
Filed: March 23, 2026

Executive Compensation

Compensation reported for Baxter International’s named executive officers, including salary, stock awards, incentive compensation, other compensation, and total compensation.

Named executive officer compensation
Executive	Position	Salary	Stock Awards	Incentives	Option Awards	Other	Reported total
Andrew Hider	President and CEO	$499,315	$23,133,518	$1,820,125	$3,185,053	$1,167,171	$29,805,182
Joel Grade	Former Executive Vice President and CFO	$827,825	$5,809,671	$459,000	$1,049,372	$63,700	$8,209,568
José E. Almeida	Former Chair Of The Board, President And Ceo	$660,420	$0	$0	$0	$7,005,624	$7,666,044
Heather Knight	Former Executive Vice President, Coo And Interim Group President, Medical Products & Therapies	$747,123	$4,018,281	$0	$1,267,349	$41,795	$6,074,548
Reazur Rasul	Executive Vice President And Group President, Healthcare Systems & Technologies	$800,000	$2,953,421	$488,000	$931,507	$73,286	$5,246,214
Alok Sonig	Former Executive Vice President And Group President, Pharmaceuticals	$779,747	$3,375,371	$0	$1,064,578	$19,577	$5,239,273
Brent Shafer		$701,644	$2,400,815	$654,839	$0	$52,695	$3,809,993
David Rosenbloom	Executive Vice President And General Counsel	$760,000	$1,989,036	$348,840	$627,345	$68,943	$3,794,164
Cecilia Soriano	Group President, Infusion Therapies & Technologies And Pharmaceuticals	$668,247	$1,300,147	$366,732	$253,472	$66,243	$2,654,841

Andrew Hider
President and CEO
$29.8M
Reported total
Salary
$499,315
Stock awards
$23,133,518
Incentives
$1,820,125
Option awards
$3,185,053
Other
$1,167,171
Joel Grade
Former Executive Vice President and CFO
$8.2M
Reported total
Salary
$827,825
Stock awards
$5,809,671
Incentives
$459,000
Option awards
$1,049,372
Other
$63,700
José E. Almeida
Former Chair Of The Board, President And Ceo
$7.7M
Reported total
Salary
$660,420
Stock awards
$0
Incentives
$0
Option awards
$0
Other
$7,005,624
Heather Knight
Former Executive Vice President, Coo And Interim Group President, Medical Products & Therapies
$6.1M
Reported total
Salary
$747,123
Stock awards
$4,018,281
Incentives
$0
Option awards
$1,267,349
Other
$41,795
Reazur Rasul
Executive Vice President And Group President, Healthcare Systems & Technologies
$5.2M
Reported total
Salary
$800,000
Stock awards
$2,953,421
Incentives
$488,000
Option awards
$931,507
Other
$73,286
Alok Sonig
Former Executive Vice President And Group President, Pharmaceuticals
$5.2M
Reported total
Salary
$779,747
Stock awards
$3,375,371
Incentives
$0
Option awards
$1,064,578
Other
$19,577
Brent Shafer
$3.8M
Reported total
Salary
$701,644
Stock awards
$2,400,815
Incentives
$654,839
Option awards
$0
Other
$52,695
David Rosenbloom
Executive Vice President And General Counsel
$3.8M
Reported total
Salary
$760,000
Stock awards
$1,989,036
Incentives
$348,840
Option awards
$627,345
Other
$68,943
Cecilia Soriano
Group President, Infusion Therapies & Technologies And Pharmaceuticals
$2.7M
Reported total
Salary
$668,247
Stock awards
$1,300,147
Incentives
$366,732
Option awards
$253,472
Other
$66,243

Andrew Hider

President and CEO

$29.8M

Reported total · FY2025 · SCT Total as filed

Source: DEF 14A Summary Compensation Table, filed March 23, 2026.

Salary: $499K
Stock Awards: $23.1M
Option Awards: $3.2M
Incentives: $1.8M
Other: $1.2M

Historical Compensation

Andrew Hider total compensation, fiscal years 2025–2025.

Year-by-year total compensation
Fiscal Year	Salary	Stock Awards	Total Compensation
2025	$499,315	$23,133,518	$29,805,182

Named Executive Officers

Andrew Hider

President and CEO

Baxter International · BAX

$29.8M

FY 2025 · DEF 14A

José E. Almeida

Former Chair Of The Board, President And Ceo

Baxter International · BAX

$7.7M

FY 2025 · DEF 14A

Brent Shafer

Baxter International · BAX

$3.8M

FY 2025 · DEF 14A

Joel Grade

Former Executive Vice President and CFO

Baxter International · BAX

$8.2M

FY 2025 · DEF 14A

Heather Knight

Former Executive Vice President, Coo And Interim Group President, Medical Products & Therapies

Baxter International · BAX

$6.1M

FY 2025 · DEF 14A

Reazur Rasul

Executive Vice President And Group President, Healthcare Systems & Technologies

Baxter International · BAX

$5.2M

FY 2025 · DEF 14A

David Rosenbloom

Executive Vice President And General Counsel

Baxter International · BAX

$3.8M

FY 2025 · DEF 14A

Alok Sonig

Former Executive Vice President And Group President, Pharmaceuticals

Baxter International · BAX

$5.2M

FY 2025 · DEF 14A

Cecilia Soriano

Group President, Infusion Therapies & Technologies And Pharmaceuticals

Baxter International · BAX

$2.7M

FY 2025 · DEF 14A

Source information

Company: Baxter International Inc
Ticker: BAX · NYSE
Filing type: DEF 14A
Fiscal year: 2025
Filing date: March 23, 2026
SEC accession number: 0001628280-26-020330

Source: U.S. Securities and Exchange Commission, DEF 14A Summary Compensation Table. View SEC filing

Related Companies

Johnson & Johnson

JNJ · NYSE

Joaquin Duato

Chairman/CEO

$32.8M

FY 2025 reported total

View company →

UnitedHealth

UnitedHealth Group Incorporated

UNH · NYSE

Stephen Hemsley

Chief Executive Officer

$60.9M

FY 2025 reported total

View company →

AbbVie

AbbVie Inc.

ABBV · NYSE

Robert A. Michael

Chairman Of The Board And Chief Executive Officer

$32.5M

FY 2025 reported total

View company →

Abbott

Abbott Laboratories

ABT · NYSE

Robert B. Ford

Chairman Of The Board And Chief Executive Officer

$24.2M

FY 2025 reported total

View company →